AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05996315 — intervention group
Intervention type: OTHER
Intervention: Supracondylar radial nerve block
Description: A patient who presents to the emergency department with a suspected distal end radius fracture will be assessed with a baseline NRS score1 and given analgesics if needed. Further they will be sent for an x-ray. If the X ray-shows a distal end radius fracture a decision to give supracondylar radial nerve block will be taken as per the choice of the treating physician. Patients who do not meet the exclusion criteria are excluded from the study at this phase.
Study NCT04729010 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture to treat anxiety in Parkinson disease
Description: Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
Study NCT04883190 — intervention group
Intervention type: OTHER
Intervention: Fulfilling Questionaires
Description: Fulfilling Questionaires PHQ-D (brief) and FSMC
Study NCT06471894 — intervention group
Intervention type: RADIATION
Intervention: Magnetic resonance imaging scanning
Description: Perform brain diffusion imaging, magnetic resonance spectroscopy, and functional magnetic resonance imaging scans on all individuals
Study NCT06471894 — intervention group
Intervention type: DRUG
Intervention: FMT Protocol
Description: Treatment of disease groups (UC and CD) using prepared fecal microbiota transplantation solution
Study NCT05436951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief on-shift nap
Description: The brief nap opportunity will allow for a 45-minute nap between the hours of 0200 and 0300 during the in-lab 12-hour simulated night shift.
Study NCT06137716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with a Robotic Hand Exoskeleton
Description: The rehabilitation program extended over six consecutive weeks. Each therapy session, lasting 45 minutes, occurred four times per week, resulting in a total of 24 sessions. Within each session, a total of six exercises, consisting of three passive exercises and three bilateral exercises, were performed in an alternating manner. The exercises were executed in the following sequence: 1) Bilateral hand opening and closing; 2) Passive independent finger opening and closing; 3) Bilateral pinch; 4) Passive hand opening and closing; 5) Bilateral hand opening and closing based on a VR-based game involving squeezing an orange; 6) Passive pinch.
Study NCT06375759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subarachnoid-Subarachnoid (S-S) Bypass
Description: The dura was widely exposed beyond the level of trauma, and then a midline dural opening was made under an operative microscope. When dura and arachnoid were adhered because of an expansion of arachnoiditis, they had to be released with great care to place the bypass tubes. During this procedure, S-S bypass was not usually needed to performed arachnoid lysis. This exposure had to reach the normal arachnoid mater free from arachnoiditis and adhesion, with normal CSF circulation.~After dissections of the normal arachnoid mater at the cephalic and caudal sites, 1 or 2 tubes made of medical grade silicone (ventricular drainage tube; internal diameter 1.5-2.0 mm, external diameter 2.5-3.3 mm) were inserted into the cephalic and caudal ends of the normal subarachnoid space. The part of the tube inserted into the subarachnoid space was approximately 2 cm long.
Study NCT06375759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intradural Adhesion Lysis
Description: Intradural spinal cord Adhesion Lysis
Study NCT04697589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Memophenol 300 mg
Description: 300 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
Study NCT04697589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Memophenol 600 mg
Description: 600 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
Study NCT04697589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Colored maltodextrin
Study NCT04715763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan Oral Product
Description: Angiotensin Receptor Blocker (ARB) FDA approved for use in hypertension and for cardiovascular risk reduction
Study NCT04715763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules filled with an inactive ingredient
Study NCT05083104 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory investigations on coagulation profiles
Description: CBC ,PT ,aPTT ,Protein C .Protein S ,ATIII and vWF
Study NCT06189651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wrist splint
Description: The same type of wrist splint to be used for at least 8 hours at night for 4 weeks, to be worn in a neutral position and in accordance with the wrist as described in previous studies to restrict movement in the wrist. Patients who did not sleep for 8 hours were asked to complete 8 hours of wrist splint use before going to sleep or after waking up.
Study NCT05577390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraneural Facilitation Therapy Treatment
Description: Intraneural Facilitation Therapy uses three manual holds to bias blood flow to closed endoneurial capillaries. The first is the facilitation hold, which is thought to pressurize the nervous system and bias circulation from the artery into the epineurium. This hold stretches the nerve further than the artery, increasing the amount of elastin in the artery and enlarging the opening of the arterial junction increasing blood into the epineurium. The secondary hold then increases epineurial blood into the transperineurial vessels increasing pressure into the endoneurial capillaries of the site being treated. The third hold, known as the sub hold, encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of Bernoulli's principle. The series of stretches will be repeated on the affected side for the treatment duration.
Study NCT05577390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physical Therapy Treatment
Description: The standard physical therapy treatment includes muscle stretching, balance, and strengthening exercises known to improve neuropathy symptoms.
Study NCT04479475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive care through community support persons
Description: The adapted B-SBNT involves families and the wider social networks of people receiving MMT to support recovery. Key components of the intervention include: mapping the social networks of clients; inviting others identified through the mapping to participate in the intervention; building communication strategies with network members; and developing joint activities with network members, e.g., income-generating activities. MMT client participants attend seven sessions over the course of six weeks: (1) Introduction, (2) Working in a social network-based setting, (3) Setting drinking and drug use goals, (4) Coping skills 1, (5), Coping Skills 2, (6) Making lifestyle changes, (7) Generating income. Social support persons attend up to five sessions over the course of six weeks.
Study NCT06189651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 5% dextrose injection using USG-guided nerve hydrodissection method
Description: 2 ml each of 5% dextrose injection was administered once at the proximal wrist level above the median nerve separating the median nerve from the flexor retinaculum and below the median nerve separating the median nerve from the flexor tendons by nerve hydrodissection method in the transverse inplane plane under ultrasound guidance. After the application, the spread of the injectate was observed by looking longitudinally at the median nerve.
Study NCT06228547 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Standardized questionnaire specifically made for the study. The interview lasts approximately 15 minutes. The form gathers baseline characteristics of the patients such as socio-demographic information, symptoms, lifestyle factors and gynecological history. The questionnaire focuses also on the manner in which the diagnosis was revealed to the patient and their experience of this disclosure. Lastly, the questionnaire includes items issued from French practice guidelines concerning etiological investigations, fertility assessment, osteoporotic and cardiovascular complications, HRT use, and residual symptoms
Study NCT05281185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended half-life FVIII concentrates with PK-guided dosing
Description: Extended half-life FVIII concentrates with PK-guided dosing as low-dose factor replacement prophylaxis (10-20u/kg, 2-3 times/week) for 6 months in severe haemophilia A patients that previously receive weight-based factor replacement prophylaxis
Study NCT05281185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard half-life FVIII concentrates with weight-based dosing
Description: standard half-life FVIII concentrates with weight-based dosing, that current patients' regimen before enrolling in this study
Study NCT04997785 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Pericapsular Nerve Group (PENG) Block
Description: PENG blocks is performed by Emergency Medicine board-certified emergency physicians (EPs) with standard training program. PENG block is performed using a spinal needle (NIPRO® 21G × 70 mm) at the level of of anterior superior iliac spine, parallel to the inguinal crease, with real-time ultrasound guidance, according to the steps published by Girón-Arango et al in 2018. The investigators use 20 ml of 1% lidocaine for nerve block because this drug has a short onset time, which is adequate to relieve pain before surgical intervention.
Study NCT04997785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Pericapsular Nerve Group (PENG) Block
Description: PENG blocks is performed by Emergency Medicine board-certified emergency physicians (EPs) with standard training program. PENG block is performed using a spinal needle (NIPRO® 21G × 70 mm) at the level of of anterior superior iliac spine, parallel to the inguinal crease, with real-time ultrasound guidance, according to the steps published by Girón-Arango et al in 2018. The investigators use 20 ml of 1% lidocaine for nerve block because this drug has a short onset time, which is adequate to relieve pain before surgical intervention.
Study NCT05696678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
Study NCT05696678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2%
Description: Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.
Study NCT05049941 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lactat and blood gases
Description: observational
Study NCT05316233 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VOLITE XC
Description: Intradermal Injection
Study NCT05316233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOLITE XC
Description: Intradermal Injection
Study NCT05316233 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VOLITE XC
Description: Subdermal Injection
Study NCT05316233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOLITE XC
Description: Subdermal Injection
Study NCT05031494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH003
Description: YH003 will be dosed at RP2D every 3 weeks. The first infusion of YH003 should be administered over 60 minutes.
Study NCT05031494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab will be administered at a dose of 240 mg every 3 weeks.
Study NCT05031494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered each 21-day cycle.
Study NCT05031494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administrated each 21-day cycle.
Study NCT05926674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release
Description: Myofascial release is a manual therapy technique commonly used by clinicians and bodyworkers to provide effects such as decreased pain, improvement in flexibility, ROM, and quality of life. It combines non-gliding fascial traction with varying amounts of stretching to produce a tensional force on the muscle and its associated fascia resulting in viscoelastic lengthening and deformation.
Study NCT05926674 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light Touch Contact
Description: The sham treatment of light touch will be applied to the lumbar spine and this form of contact is not therapeutic. It is only meant to only mimic a manual therapy technique.
Study NCT06232187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence feedback for ultrasound EFW standard plane images
Description: AI feedback in two levels, in aid of the participants, to obtain the right standardplane images used in fetal ultrasound EFW calculation.
Study NCT04767815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet A group
Description: Fasting + DWN12088 200 mg
Study NCT04767815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet B group
Description: 30 minutes after a high-fat meal + DWN12088 200 mg
Study NCT06131294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride Application (Experimental Fluoride Application)
Description: Fluoride containing applications are applied on white spot lesions. First solution was air-dried before the second application with the other component was done.
Study NCT06131294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluor Protector S
Description: Fluor Protector S is applied on white spot lesions.
Study NCT06482801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab
Description: This study has 3 subgroups:~Arm 1. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab is administrated with a total dose of 1-2mg/kg via intra-tumor fine needle injection in 10 min, every 3 weeks.~Arm 2. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin is administrated via intra-tumor fine needle injection in 15 min, every 3 weeks.~Arm 3. Ipilimumab +pembrolizumab or Ipilimumab +durvalumab combined with idarubicin plus bevacizumab is administrated via intra-tumor fine needle injection in 20 min, every 3 weeks.
Study NCT04767815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diet C group
Description: 2 hours after a high-fat meal + DWN12088 200 mg
Study NCT05155358 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood test
Description: Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis
Study NCT04649645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TOBACCO CIGARETTES
Description: Participants in Arm A will continue smoking their own cigarette brand as usual.
Study NCT04649645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)
Description: Participants in Arm B will trial and familiarize with a selection of C-F NDS in order to choose the product of their preference. They will be trained and counselled on the chosen C-F NDS. Prior to check-out, participants wishing to use a heated tobacco device will receive one kit and a full 2 weeks supply of tobacco sticks of their choice (they will receive a number of tobacco sticks per day corresponding to the number of cigarettes smoked at baseline); those wishing to use a vaping product will receive one vaping kit and a full 2 weeks supply of e-liquids of their choice (they will receive twelve 10 ml refill containers).
Study NCT04649645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NOT SMOKING
Description: Participants in Arm C will continue not smoking or use any form of tobacco or nicotine-containing products.
Study NCT06498947 — intervention group
Intervention type: OTHER
Intervention: This study was observational with no intervention.
Description: This study was observational with no intervention.
Study NCT05609240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: See arm/group description
Study NCT01970111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373, High dose
Study NCT01970111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373, Low dose
Study NCT05901168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Video Games Intervention
Description: Participants will complete active video games in the same order until they fill 20 minutes after the first 5 minutes of warm-up. In addition, during the change between games (lasting approximately 20 seconds), patients will be instructed by a therapist to perform combined exercises to minimize immobility time. These exercises are: elbow flexion and foot flexion, shoulder flexion and unilateral hip extension, and arm abduction and squat exercises that will prevent the patient from cooling down.
Study NCT05901168 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Exercise Intervention
Description: Active exercises for the upper extremities (without support): Shoulder flexion, Shoulder abduction, Elbow flexion at shoulder 90° flexion.~Active exercises for the lower extremities: Ankle-foot movements (ankle pumping exercise), heel raise, Knee extension in sitting high, Hip-knee flexion while lying supine~Body: Bridging, Trunk rotations in sitting~These exercises will be done in 1 set of 8-10 repetitions.~It will take about 20 minutes.
Study NCT05684315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: soft tissue flossing therapy
Description: BFRT and tissue threading is a therapy that involves applying external pressure below or above a joint or muscle of a selected limb, usually with a circumferential elastic band. The pressure provided by the rolled band securely maintains arterial blood supply but reduces or blocks venous outflow distal to the site.
Study NCT05248022 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug-eluting beads bronchial arterial chemoembolization
Description: Drug-eluting beads bronchial arterial chemoembolization generally uses platinum-containing two-drug chemotherapy platinum (cisplatin, carboplatin, nedaplatin) combined treatment, and drug-loaded microspheres can be loaded with vinorelbine, gemcitabine, irinote Kang, raltitrexed. The dose of chemotherapy drugs is set to 75mg/m2 of platinum, and the dose of chemotherapy through catheter infusion is reduced by 25%. The dose of drug-loaded drugs is vinorelbine 25mg/m2, gemcitabine generally 1000mg/m2, irinotecan 80mg/ m2, raltitrexed 4mg. Chemotherapy was perfused first, followed by embolization with drug-loaded microspheres, until the blood flow in the artery supplying the tumor slowed down and approached stagnation. The number of DEB-BACE treatments is determined by the investigator, and is given as needed according to the patient's condition, usually 1-2 times, with an interval of 28±10 days.
Study NCT05231694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nerver growth factor (NGF) injection
Description: The 20ug nerve growth factor (NO.S20060051, Jinlujie) will be obtained from Hiteck Biopharmaceutical Co., Ltd, Wuhan, China. mNGF will be dissolved in 1 ml sterile water for injection and then injected intramuscularly at gluteal muscle, once a day for 4 weeks. Dose modification is not allowed for mNGF.
Study NCT05231694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo injection
Description: The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
Study NCT06429163 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration of the anterior abdominal wall
Description: Infiltration of the anterior abdominal wall is performed with 0.2% ropivacaine diluted with physiological saline on a syringe in the volume of 20 ml - 5 ml for each incision. The drug is injected with a 22-gauge needle at a 90-degree angle.
Study NCT06429163 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Infiltration of the anterior abdominal wall
Description: Infiltration of the anterior abdominal wall is performed with 0.2% ropivacaine diluted with physiological saline on a syringe in the volume of 20 ml - 5 ml for each incision. The drug is injected with a 22-gauge needle at a 90-degree angle.
Study NCT06429163 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper hypogastric plexus blockade
Description: At the beginning of the operation the camera is used to visualise the area of the promontorium. Next, a 1 mm laparoscopic puncture needle is inserted through a trocar in the suprapubic region and plunged into the upper part of the formed dome to a depth of no more than 1 cm. After positioning the needle retroperitoneally, an aspiration test is performed to prevent intravascular injection. Then, 20 ml of 0.2% ropivacaine diluted with physiological saline is slowly injected. At the end of the procedure, the retroperitoneal space swollen by the local anaesthetic is visualised in the promontorium.